We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MO faces cigarette-volume declines, weaker oral tobacco results and downward EPS estimate revisions.
Altria Group, Inc. (MO - Free Report) is currently trading at a compelling discount to the industry, sector and the broader market, positioning it as a potential value opportunity for long-term investors. The stock’s forward 12-month price-to-earnings (P/E) ratio stands at 12.1. This is below the Tobacco industry’s average of 15.47, the Consumer Staples sector’s 16.95 and the S&P 500’s 19.65.
MO P/E Ratio (Forward 12 Months)
Image Source: Zacks Investment Research
When measured against leading competitors, Philip Morris International Inc. (PM - Free Report) , Turning Point Brands, Inc. (TPB - Free Report) and British American Tobacco p.l.c. (BTI - Free Report) , Altria’s relative valuation presents a mixed picture. Philip Morris and Turning Point Brands trade at higher multiples of 21.43x and 30.60x, respectively, while British American Tobacco trades at a lower multiple of 10.98x.
In terms of share performance, Altria has gained 9.6% over the past month, outperforming both the industry and the sector, which advanced 5.1% and 0.9%, respectively, over the same period. In comparison, the S&P 500 declined 1.8%. Among its peers, Altria also outperformed Philip Morris and British American Tobacco, which gained 3.9% and 0.7%, respectively. Turning Point Brands declined 17.8% at the same period.
MO Stock Past Month Performance
Image Source: Zacks Investment Research
Technical indicators highlight Altria’s strength, with the stock last trading at $70.10, above its 50-day and 200-day moving averages of $68.29 and $64.60, respectively, signaling solid upward momentum. This technical setup points to positive sentiment surrounding the stock.
MO Stock Trades Above 50-Day & 200-Day Moving Averages
Image Source: Zacks Investment Research
So far, Altria’s attractive valuation, steady stock performance and supportive technical indicators underscore its market appeal. To fully grasp what is driving this momentum and assess the long-term potential, it is critical to examine Altria’s underlying fundamentals, where earnings resilience, portfolio diversification and strategic growth initiatives become evident.
Altria: Strength Built on Pricing and Portfolio Strategy
Altria continues to demonstrate earnings resilience through disciplined pricing and strong execution. In the second quarter of 2026, adjusted EPS increased 2.8% year over year to $1.48, while first-half adjusted EPS rose 4.9% to $2.80. Smokeable products remained a key earnings contributor, with higher pricing helping offset lower shipment volumes and increased promotional investments. This ability to protect profitability amid volume pressure remains an important strength.
Altria is strengthening its smoke-free portfolio, with on! PLUS showing encouraging early traction. In the second quarter, on!’s share of the overall oral tobacco category increased both sequentially and year over year, although its share within the nicotine-pouch category remained below the prior-year level. Helix expanded on! PLUS to 120,000 stores nationwide and resumed shipments of the 12-milligram product in select states. The company plans a national expansion of the 12-milligram on! PLUS offering, followed by additional flavors across multiple nicotine strengths. Management believes these initiatives can broaden on!’s consumer appeal and strengthen its position in the nicotine-pouch category.
At the same time, Altria is using a data-driven, total-portfolio approach to strengthen its traditional tobacco business. Marlboro Cowboy Cut generated strong interest among premium smokers, while Basic continued to gain traction in the discount segment during the second quarter. This strategy allows Altria to address different consumer preferences while using pricing and portfolio management to support smokeable products’ profitability despite declining cigarette volumes.
What Could Weigh on MO’s Growth?
Altria continues to face pressure from declining cigarette volumes, which remains a key challenge for its traditional tobacco business. In the second quarter of 2026, domestic cigarette shipment volume declined 3.2% year over year, while inventory-adjusted volume fell an estimated 4.5%. Higher pricing helped offset some of the volume weakness, but increased promotional investments and a greater mix of discount shipments also weighed on performance.
The oral tobacco business is another area of concern. Second-quarter net revenues in the segment declined 5.3%, while adjusted OCI fell 8%. Shipment volume decreased 8.5% due to retail share losses and trade inventory movements, partially offset by industry growth. This weakness highlights the challenge of transitioning the portfolio toward smoke-free products while maintaining profitability across the broader oral tobacco business.
Altria Witnessing Downward Estimate Revision
Reflecting cautious sentiment around Altria, the Zacks Consensus Estimate for EPS has seen downward revisions. Over the past 60 days, the EPS estimate for 2026 and 2027 fell 3 cents each to $5.67 and $5.84, respectively.
Image Source: Zacks Investment Research
What Is the Right Investment Strategy for MO?
Altria’s attractive valuation, resilient earnings and strong pricing power remain key positives. Progress with on! PLUS and disciplined portfolio management also provide avenues for longer-term growth. However, persistent cigarette-volume declines, weakness in oral tobacco and downward estimate revisions temper the near-term outlook. With the stock already showing strong price momentum, further upside may depend on stronger operating trends and a recovery in earnings expectations. Existing investors may consider holding their positions, while prospective investors could wait for a more favorable entry point. Altria currently carries a Zacks Rank #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
Altria Stock Trades at a Discount: Should You Buy, Sell or Hold?
Key Takeaways
Altria Group, Inc. (MO - Free Report) is currently trading at a compelling discount to the industry, sector and the broader market, positioning it as a potential value opportunity for long-term investors. The stock’s forward 12-month price-to-earnings (P/E) ratio stands at 12.1. This is below the Tobacco industry’s average of 15.47, the Consumer Staples sector’s 16.95 and the S&P 500’s 19.65.
MO P/E Ratio (Forward 12 Months)
Image Source: Zacks Investment Research
When measured against leading competitors, Philip Morris International Inc. (PM - Free Report) , Turning Point Brands, Inc. (TPB - Free Report) and British American Tobacco p.l.c. (BTI - Free Report) , Altria’s relative valuation presents a mixed picture. Philip Morris and Turning Point Brands trade at higher multiples of 21.43x and 30.60x, respectively, while British American Tobacco trades at a lower multiple of 10.98x.
In terms of share performance, Altria has gained 9.6% over the past month, outperforming both the industry and the sector, which advanced 5.1% and 0.9%, respectively, over the same period. In comparison, the S&P 500 declined 1.8%. Among its peers, Altria also outperformed Philip Morris and British American Tobacco, which gained 3.9% and 0.7%, respectively. Turning Point Brands declined 17.8% at the same period.
MO Stock Past Month Performance
Image Source: Zacks Investment Research
Technical indicators highlight Altria’s strength, with the stock last trading at $70.10, above its 50-day and 200-day moving averages of $68.29 and $64.60, respectively, signaling solid upward momentum. This technical setup points to positive sentiment surrounding the stock.
MO Stock Trades Above 50-Day & 200-Day Moving Averages
Image Source: Zacks Investment Research
So far, Altria’s attractive valuation, steady stock performance and supportive technical indicators underscore its market appeal. To fully grasp what is driving this momentum and assess the long-term potential, it is critical to examine Altria’s underlying fundamentals, where earnings resilience, portfolio diversification and strategic growth initiatives become evident.
Altria: Strength Built on Pricing and Portfolio Strategy
Altria continues to demonstrate earnings resilience through disciplined pricing and strong execution. In the second quarter of 2026, adjusted EPS increased 2.8% year over year to $1.48, while first-half adjusted EPS rose 4.9% to $2.80. Smokeable products remained a key earnings contributor, with higher pricing helping offset lower shipment volumes and increased promotional investments. This ability to protect profitability amid volume pressure remains an important strength.
Altria is strengthening its smoke-free portfolio, with on! PLUS showing encouraging early traction. In the second quarter, on!’s share of the overall oral tobacco category increased both sequentially and year over year, although its share within the nicotine-pouch category remained below the prior-year level. Helix expanded on! PLUS to 120,000 stores nationwide and resumed shipments of the 12-milligram product in select states. The company plans a national expansion of the 12-milligram on! PLUS offering, followed by additional flavors across multiple nicotine strengths. Management believes these initiatives can broaden on!’s consumer appeal and strengthen its position in the nicotine-pouch category.
At the same time, Altria is using a data-driven, total-portfolio approach to strengthen its traditional tobacco business. Marlboro Cowboy Cut generated strong interest among premium smokers, while Basic continued to gain traction in the discount segment during the second quarter. This strategy allows Altria to address different consumer preferences while using pricing and portfolio management to support smokeable products’ profitability despite declining cigarette volumes.
What Could Weigh on MO’s Growth?
Altria continues to face pressure from declining cigarette volumes, which remains a key challenge for its traditional tobacco business. In the second quarter of 2026, domestic cigarette shipment volume declined 3.2% year over year, while inventory-adjusted volume fell an estimated 4.5%. Higher pricing helped offset some of the volume weakness, but increased promotional investments and a greater mix of discount shipments also weighed on performance.
The oral tobacco business is another area of concern. Second-quarter net revenues in the segment declined 5.3%, while adjusted OCI fell 8%. Shipment volume decreased 8.5% due to retail share losses and trade inventory movements, partially offset by industry growth. This weakness highlights the challenge of transitioning the portfolio toward smoke-free products while maintaining profitability across the broader oral tobacco business.
Altria Witnessing Downward Estimate Revision
Reflecting cautious sentiment around Altria, the Zacks Consensus Estimate for EPS has seen downward revisions. Over the past 60 days, the EPS estimate for 2026 and 2027 fell 3 cents each to $5.67 and $5.84, respectively.
Image Source: Zacks Investment Research
What Is the Right Investment Strategy for MO?
Altria’s attractive valuation, resilient earnings and strong pricing power remain key positives. Progress with on! PLUS and disciplined portfolio management also provide avenues for longer-term growth. However, persistent cigarette-volume declines, weakness in oral tobacco and downward estimate revisions temper the near-term outlook. With the stock already showing strong price momentum, further upside may depend on stronger operating trends and a recovery in earnings expectations. Existing investors may consider holding their positions, while prospective investors could wait for a more favorable entry point. Altria currently carries a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.